Menu

Periodic Fasting Improves Rodent Health

And a diet that includes a few days of caloric restriction each month reduces biomarkers of aging and disease in people, according to a small trial.

Jun 18, 2015
Kerry Grens

PIXABAY, MOJZAGREBINFOIn animal studies, bouts of fasting are shown to protect against aging-related diseases, suggesting that periodic fasting may benefit humans, too. But to cut out food for days at a time is no easy feat for most people, so researchers have designed a diet that mimics fasting without making dieters completely abstain from eating.

A short-term study of the diet in a small group of people published today (June 18) in Cell Metabolism yielded promising results. Biomarkers predictive of cancer, diabetes, and heart disease risk dropped among participants on the fasting diet, compared to those who maintained their normal eating habits.

“This single dietary change can counteract all these variables of aging, and I think that’s very impressive,” molecular biologist Christopher Hine of the Harvard School of Public Health told Science.

The researchers who conducted the study did not actually measure whether people’s health improved. Valter Longo of the University of Southern California who led the work told The Telegraph, “I think based on the markers for ageing and disease in humans it has the potential to add a number of years of life but more importantly to have a major impact on diabetes, cancer, heart disease and other age-related disease.”

The diet consists of five continuous days of caloric restriction each month. Participants ate prepared foods of vegetable soups, energy bars and drinks, tea, and a supplement amounting to 1,090 calories on day one and 725 calories for each of the other four days. “It’s not like eating ravioli, but it is better than going without,” Longo told Science. The rest of the month the volunteers could eat normally.

In mice, a similar regime did show health benefits—in particular, longer lifespan, less bone loss, and fewer cancers.

“This is arguably the first non-chronic pre-clinically and clinically tested anti-aging and healthspan-promoting intervention shown to work and to be very feasible as a doctor or dietitian-supervised intervention,” Longo said in a press release.

Longo said clinical trials are planned to test the intervention among larger numbers of people. One of the questions Naveed Sattar, a professor at the University of Glasgow, raised was whether people can stick to it. “The best way to alter weight trajectory or to lose weight is to make permanent and sustainable changes in one’s dietary composition,” Sattar, who was not involved in the work, told The Telegraph. “This way, folk can eat three meals a day and still have total less calorie intake than they had previously. This, for me, is better for mind and body, and critically, more sustainable.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.